Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H15NO3.ClH |
Molecular Weight | 185.649 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OCCN(CCO)CCO
InChI
InChIKey=HHLJUSLZGFYWKW-UHFFFAOYSA-N
InChI=1S/C6H15NO3.ClH/c8-4-1-7(2-5-9)3-6-10;/h8-10H,1-6H2;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H15NO3 |
Molecular Weight | 149.1882 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TROLAMINE&audience=professional;Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/11340s16lbl.pdf; https://www.ons.org/intervention/trolamine-biafine®; https://www.ncbi.nlm.nih.gov/pubmed/?term=15084618; https://clinicaltrials.gov/ct2/show/NCT02729324; http://www.ncbi.nlm.nih.gov/pubmed/18441842
Sources: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TROLAMINE&audience=professional;
Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/11340s16lbl.pdf; https://www.ons.org/intervention/trolamine-biafine®; https://www.ncbi.nlm.nih.gov/pubmed/?term=15084618; https://clinicaltrials.gov/ct2/show/NCT02729324; http://www.ncbi.nlm.nih.gov/pubmed/18441842
Trolamine, an organic compound, is the salt formed between triethanolamine and salicylic acid. It is widely used as a topical analgesic. 10% trolamine salicylate medical products sold over-the-counter such as are creams for temporarily relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, lumbago, neuralgia, strains, bruises, and sprains. The FDA approved in 1958 otic solution drops containing triethanolamine polypeptide used in the ear to break down and loosen earwax was discontinued. Trolamine can enhance skin healing by recruiting macrophages and modifying the concentrations of various immunomodulators. Trolamine (Biafine; Genmedix Ltd, France) is commonly prescribed at the beginning of radiotherapy for preventing acute radiation-induced skin toxicity in China. Biafine has been studied in radiodermatitis and Phase 2 clinical trial has been initiated in 2016 by Sun Yat-sen University to establish the efficacy of trolamine (Biafine) for the management of radiation dermatitis in patients with nasopharyngeal carcinoma receiving IMRT.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Inactive ingredient | Volu-Firm Approved UseUnknown |
|||
Palliative | CERUMENEX Approved UseFor removal of impacted cerumen prior to ear examination, otologic therapy and/or audiometry. CERUMENEX Eardrops should be used only with caution in external otitis. Launch Date1958 |
Doses
Dose | Population | Adverse events |
---|---|---|
5.38 mg 2 times / day multiple, topical Studied dose Dose: 5.38 mg, 2 times / day Route: topical Route: multiple Dose: 5.38 mg, 2 times / day Sources: |
unhealthy, 21.6–84.9 Health Status: unhealthy Age Group: 21.6–84.9 Sex: M+F Sources: |
Disc. AE: Application site erythema... AEs leading to discontinuation/dose reduction: Application site erythema (6.7%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Application site erythema | 6.7% Disc. AE |
5.38 mg 2 times / day multiple, topical Studied dose Dose: 5.38 mg, 2 times / day Route: topical Route: multiple Dose: 5.38 mg, 2 times / day Sources: |
unhealthy, 21.6–84.9 Health Status: unhealthy Age Group: 21.6–84.9 Sex: M+F Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Preliminary assessment of selected methacrylic acid--acrylic acid copolymers as factors buffering triethanolamine interacting with artificial skin sebum. | 2001 |
|
[Enantiomeric separation of drugs with capillary electrophoresis with cyclodextrins]. | 2001 |
|
Fluorescent derivatization of nitrite ions with 2,3-diaminonaphthalene utilizing a pH gradient in a Y-shaped microchannel. | 2001 Apr |
|
Comparative studies of various run buffers for chiral capillary electrophoresis using chiral crown ether as a chiral selector. | 2001 Dec |
|
In vitro percutaneous absorption of tenoxicam from pressure-sensitive adhesive matrices across the hairless mouse skin. | 2001 Dec |
|
[Determination of sulfite residues in foods by using the modified rankine apparatus and HPLC]. | 2001 Oct |
|
Use of ferric chloride to identify salicylate-containing poisons. | 2002 |
|
Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. | 2002 Apr 2 |
|
Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. | 2002 Apr 22 |
|
Quantitation of nicotine in tobacco products by capillary electrophoresis. | 2002 Jan-Feb |
|
Synthesis and characterization of mesoporous indium tin oxide possessing an electronically conductive framework. | 2002 Jul 24 |
|
Physicochemical determinants of linear alkylbenzene sulfonate (LAS) disposition in skin exposed to aqueous cutting fluid mixtures. | 2002 Jun |
|
Amines compounds as inhibitors of PCDD/Fs de novo formation on sintering process fly ash. | 2002 Jun 15 |
|
Photobleaching of a solid photochromic medium by a Gaussian laser beam. | 2002 May 20 |
|
Assessing changes in Cd phytoavailability to tomato in amended calcareous soils. | 2002 Oct |
|
Physiological function of the maltose operon regulator, MalR, in Lactococcus lactis. | 2002 Sep 25 |
|
Coordination and fluorescence of the intracellular Zn2+ probe [2-methyl-8-(4-toluenesulfonamido)-6-quinolyloxy]acetic acid (Zinquin A) in ternary Zn2+ complexes. | 2003 Apr 2 |
|
Enantiomeric separation of TAPP, H-Tyr-(D)Ala-Phe-Phe-NH(2), by capillary electrophoresis using 18-crown-6-tetracarboxylic acid as a chiral selector. | 2003 Aug 15 |
|
The use of complexation with alkanolamines to facilitate skin permeation of mefenamic acid. | 2003 Aug 27 |
|
A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. | 2003 Dec 1 |
|
Photovoltaic properties of self-assembled monolayers of porphyrins and porphyrin-fullerene dyads on ITO and gold surfaces. | 2003 Jul 30 |
|
Capillary electrophoresis determinations of trace concentrations of inorganic ions in large excess of chloride: soft modelling using artificial neural networks for optimisation of electrolyte composition. | 2003 Jun |
|
Modification and validation of the pyromellitic acid electrolyte for the capillary electrophoretic determination of anions. | 2003 May 2 |
|
Qualitative determination of false-positive effects in the acetylcholinesterase assay using thin layer chromatography. | 2003 May-Jun |
|
Reactivity with Tris(hydroxymethyl)aminomethane confounds immunodetection of acrolein-adducted proteins. | 2003 Oct |
|
Identification of selenium species in urine by ion-pairing HPLC-ICP-MS using laboratory-synthesized standards. | 2003 Oct |
|
Molecular energy and electron transfer assemblies made of self-organized lipid-porphyrin bilayer vesicles. | 2003 Oct 6 |
|
Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine. | 2003 Sep 5 |
|
Carbopols as factors buffering triethanolamine interacting with artificial skin sebum. | 2004 |
|
Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. | 2004 Apr 15 |
|
[The problem and improvement of colorimetric method for determination of sulfite in foods containing sulfur compounds]. | 2004 Dec |
|
Analysis of Tamm-Horsfall protein by high-performance liquid chromatography with native fluorescence. | 2004 Feb 20 |
|
Mixture additives inhibit the dermal permeation of the fatty acid, ricinoleic acid. | 2004 Feb 28 |
|
Evaluation of method of preparation of passive diffusion tubes for measurement of ambient nitrogen dioxide. | 2004 Jan |
|
Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines. | 2004 Jan |
|
Evaluation of the potential of triethanolamine to alter hepatic choline levels in female B6C3F1 mice. | 2004 Jun |
|
Cubic phase prepared in an anionic/amphoteric surfactant/oleic acid/decane/water system and the relationship with the neighboring phase. | 2004 Mar 30 |
|
Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol. | 2004 May 4 |
|
A high-nuclearity "Celtic-ring" isopolyoxotungstate, [H12W36O120]12-, that captures trace potassium ions. | 2004 Nov 3 |
|
Determination of volatile corrosion inhibitors by capillary electrophoresis. | 2004 Oct 8 |
|
Patch test results with the metalworking fluid series of the German Contact Dermatitis Research Group (DKG). | 2004 Sep |
|
Functionalized metal oxide clusters: synthesis, characterization, crystal structures, and magnetic properties of a novel series of fully reduced heteropolyoxovanadium cationic clusters decorated with organic ligands--[MVIV6O6[(OCH2CH2)2N(CH2CH2OH)]6]X (M = Li, X = Cl x LiCl; M = Na, X = Cl x H2O; M = Mg, X = 2Br x H2O; M = Mn, Fe, X = 2Cl; M = Co, Ni, X = 2Cl x H2O). | 2004 Sep 20 |
|
Photopolymerization of poly(ethylene glycol) diacrylate on eosin-functionalized surfaces. | 2004 Sep 28 |
|
Photosensitized hydrogen evolution from water using conjugated polymers wrapped in dendrimeric electrolytes. | 2004 Sep 29 |
|
Co phytoavailability for tomato in amended calcareous soils. | 2005 Apr |
|
Polycationic dendrimers interact with RNA molecules: polyamine dendrimers inhibit the catalytic activity of Candida ribozymes. | 2005 Jan 21 |
|
Ion chromatographic analysis of amines, alkanolamines, and associated anions in concrete. | 2005 Mar |
|
A factor analysis for complex systems containing nimesulide. | 2005 Mar |
|
Photoreduction behavior of cytochrome c by zinc porphyrin in lipid media. | 2005 May 13 |
|
Effect of cationic micellar aggregates on the kinetics of oxidation of aminoalcohols by N-bromosuccinimide in alkaline medium. | 2005 May 15 |
Sample Use Guides
Fill ear canal with ear drops of 10% triethanolamine Polypeptide Oleate-Condensate with the patient’s head tilted at a 45° angle. Insert cotton plug and allow to remain 15-30 minutes. Then gently flush with lukewarm water, using a soft rubber syringe (avoid excessive pressure). Exposure of skin outside the ear to the drug should be avoided. The procedure may be repeated if the first application fails to clear the impaction.
Route of Administration:
Otic (auricular)
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=15850295
Penetration of triethanolamine into artificial skin sebum and its uplift were measured using 0.1 M aqueous triethanolamine solution.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:53 GMT 2025
by
admin
on
Mon Mar 31 17:50:53 GMT 2025
|
Record UNII |
R297UJ9QDY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C009546
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
R297UJ9QDY
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
R297UJ9QDY
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
101814
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
m11100
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID1052321
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
211-284-2
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
637-39-8
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | |||
|
1368178
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
132753
Created by
admin on Mon Mar 31 17:50:53 GMT 2025 , Edited by admin on Mon Mar 31 17:50:53 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |